Asset Details
Do you wish to reserve the book?
Female genital schistosomiasis and HIV/AIDS: Reversing the neglect of girls and women
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Female genital schistosomiasis and HIV/AIDS: Reversing the neglect of girls and women
Do you wish to request the book?
Female genital schistosomiasis and HIV/AIDS: Reversing the neglect of girls and women
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Female genital schistosomiasis and HIV/AIDS: Reversing the neglect of girls and women
2019
Overview
Competing interests: PJH is a patentholder and investigator on a vaccine against schistosomiasis that is in clinical trials.
Since the 2000s, we have known that female genital schistosomiasis (FGS) is likely the most neglected gynecologic condition and HIV/AIDS cofactor across sub-Saharan Africa.
[...]multiple (and peer-reviewed) scientific papers have been written on this subject [13–21], but they have largely appealed to the community of scientists and public health experts committed to NTDs.
[...]although “preaching to the converted” has helped to unify the NTDs community, it has (so far) done little to stimulate the global HIV/AIDS community toward accepting the importance of praziquantel MDA as a key component of strategies to prevent new infections of HIV/AIDS.
Realizing that declines in new HIV/AIDS infections remain too slow, especially in younger women aged 15–24 years who are twice as likely to be living with HIV than men [39]—in 25 countries, of which 18 in sub-Saharan Africa—UNAIDS launched its Prevention 2020 Road Map [40] calling for innovative combination prevention packages, in addition to HIV screening, counseling, and treatment programs.
Since 2017, several parallel sessions have taken place at international AIDS and Women’s conferences—including the 22nd International AIDS Conference held in Amsterdam, the Netherlands in 2018—calling for a more holistic approach to women’s health and HIV.
According to the WHO, despite making impressive gains in 2017, we are still falling short of meeting the minimum target of treating at least 75% of the African children who require regular and periodic administration of praziquantel [43].
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
Acquired immune deficiency syndrome
/ Adult
/ Africa
/ AIDS
/ Animals
/ Anthelmintics - therapeutic use
/ Child
/ Children
/ Complications and side effects
/ Female
/ Females
/ Genital Diseases, Female - complications
/ Genital Diseases, Female - parasitology
/ Genital Diseases, Female - prevention & control
/ Girls
/ HIV
/ HIV Infections - complications
/ HIV Infections - prevention & control
/ Human immunodeficiency virus
/ Humans
/ Medicine and Health Sciences
/ Men
/ Praziquantel - therapeutic use
/ Public health administration
/ Schistosomiasis haematobia - complications
/ Schistosomiasis haematobia - prevention & control
/ Vaccines
/ Women
